The inhibitory effect of 5-acetoxy-2-(4-acetoxyphenyl)-1-ethyl-3-methylindole (D 16726) on estrogen-dependent mammary tumors

Phase I/II study of the anti-oestrogen zindoxifene (D16726) in the treatment of advanced breast cancer. A Cancer Research Campaign Phase I/II Clinical Trials Committee study

“…The lack of efficacy of zindoxifene in our study is disappointing in comparison to the reported activity of the compound in preclinical studies (Von Angerer et al, 1985;Hilgard et al, 1988). None of the 25 patients who were eligible for response assessment had tumour regression as a result of zindoxifene treatment.…”

“…The compound has oestrogen antagonist and agonist properties, and has been shown to be effective in the treatment of rat DMBA induced mammary carcinomas (Von Angerer, 1984;Von Angerer et al, 1985;Hilgard et al, 1988). In this paper we report a phase I/II study of zindoxifene in advanced human breast cancer.…”

Phase I/II study of the anti-oestrogen zindoxifene (D16726) in the treatment of advanced breast cancer. A Cancer Research Campaign Phase I/II Clinical Trials Committee study

“…The lack of efficacy of zindoxifene in our study is disappointing in comparison to the reported activity of the compound in preclinical studies (Von Angerer et al, 1985;Hilgard et al, 1988). None of the 25 patients who were eligible for response assessment had tumour regression as a result of zindoxifene treatment.…”

“…The compound has oestrogen antagonist and agonist properties, and has been shown to be effective in the treatment of rat DMBA induced mammary carcinomas (Von Angerer, 1984;Von Angerer et al, 1985;Hilgard et al, 1988). In this paper we report a phase I/II study of zindoxifene in advanced human breast cancer.…”

Phase I/II study of the anti-oestrogen zindoxifene (D16726) in the treatment of advanced breast cancer. A Cancer Research Campaign Phase I/II Clinical Trials Committee study

“…The lack of efficacy of zindoxifene in our study is disappointing in comparison to the reported activity of the compound in preclinical studies (Von Angerer et al, 1985;Hilgard et al, 1988). None of the 25 patients who were eligible for response assessment had tumour regression as a result of zindoxifene treatment.…”

“…The compound has oestrogen antagonist and agonist properties, and has been shown to be effective in the treatment of rat DMBA induced mammary carcinomas (Von Angerer, 1984;Von Angerer et al, 1985;Hilgard et al, 1988). In this paper we report a phase I/II study of zindoxifene in advanced human breast cancer.…”

Phase I/II study of the anti-oestrogen zindoxifene (D16726) in the treatment of advanced breast cancer. A Cancer Research Campaign Phase I/II Clinical Trials Committee study

“…The lack of efficacy of zindoxifene in our study is disappointing in comparison to the reported activity of the compound in preclinical studies (Von Angerer et al, 1985;Hilgard et al, 1988). None of the 25 patients who were eligible for response assessment had tumour regression as a result of zindoxifene treatment.…”

“…The compound has oestrogen antagonist and agonist properties, and has been shown to be effective in the treatment of rat DMBA induced mammary carcinomas (Von Angerer, 1984;Von Angerer et al, 1985;Hilgard et al, 1988). In this paper we report a phase I/II study of zindoxifene in advanced human breast cancer.…”